MannKind Announces $50M Private Placement Financing, Closing Expected On Or About July 24
MannKind Corporation (NASDAQ:MNKD), a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions for cardiometabolic and orphan lung diseases, today announced
MannKind is raising $50 million by selling new shares to investors, which helps the company pay for research and operations. When a company does this, watch whether the stock price stays steady—it shows investors still believe in the company's future plans.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.